Fortress Biotech Q2 revenue rises 14% to $18.7 million; net loss of $2.5 million
Fortress Biotech reported second quarter 2026 net revenue of $18.7 million, up 14% from $16.4 million a year earlier, and a net loss attributable to common stockholders of $2.5 million, or $0.08 per share, compared with net income of $13.4 million, or $0.50 per share basic, in the second quarter of 2025. Operating expenses fell sharply, with research and development at $0.8 million versus $8.1 million and selling, general and administrative costs at $20.8 million versus $38.8 million, and cash and cash equivalents rose to $196.6 million as of June 30, 2026 from $79.4 million at December 31, 2025.
Key points
- Net revenue was $18.7 million for the quarter, of which $17.8 million came from marketed dermatology products, compared with $16.4 million a year earlier.
- Loss from operations narrowed to $10.0 million from $36.5 million, driven mainly by lower SG&A and R&D expenses.
- Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, versus net income of $13.4 million, or $0.50 per share basic, in the prior-year quarter.
- Partner Crystalys Therapeutics announced a $130 million Series B financing in July 2026 for dotinurad, on which subsidiary Urica is entitled to a 3% royalty on future net sales.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.